Endocrine Abstracts

Background: GLP-1 agonism have the potential to affect gastric emptying (GE), yet the reports for subcutaneous semaglutide, currently the most effective GLP-1 RA approved for weight management, remain inconclusive. It has been demonstrated that semaglutide either had no effect on GE or it delayed GE only within the first hour, without late phase retention. Notably, those conclusions were made by an indirect method of estimation of GE through ingestion, absorption and determina...

Aim/Introduction: [18F]fluorocholine (FCH) positron emission tomography/computed tomography (PET/CT) has gained an important role in the preoperative diagnosis of patients with primary hyperparathyroidism (pPHP). In these patients, thyroid nodules are frequently found on preoperative ultrasound. FCH PET/CT provides a high negative predictive value to reliably rule out cancer in thyroid nodules with low uptake. However, more than half of benign thyroid nodules have b...

Effective targeted therapy for advanced endocrine malignancies is a goal of modern endocrinology. We herein present promising results of the first phase of clinical part of European project (Gran-T-MTC) aimed to assess the safety of gastrin analogue CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) i.v. administration in dose (50 μg) useful for translation to 177In-CP04 for PRRT. CP04 has been selected for MTC therapy based on a high CCK-2 receptor...